# Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers

> **NCT03516305** · PHASE1 · COMPLETED · sponsor: **Engage Therapeutics, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Staccato Alprazolam 1 mg

## Key facts

- **NCT ID:** NCT03516305
- **Lead sponsor:** Engage Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-06
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516305, "Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03516305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*